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Abstract 
Macrophages and neutrophils are key components involved in the regulation of numerous chronic inflammatory 
diseases, infectious disorders, and especially certain autoimmune disease. However, little is known regarding the 
contribution of these cells to the pathogenesis of autoimmune disorders. Recent studies have aimed to clarify certain 
important factors affecting the immunogenicity of these cells, including the type and dose of antigen, the microen-
vironment of the cell-antigen encounter, and the number, subset, and phenotype of these cells, which can prevent 
or induce autoimmune responses. This review highlights the role of macrophage subsets and neutrophils in injured 
tissues, supporting their cooperation during the pathogenesis of certain autoimmune diseases.
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Background
Epithelial and mucosal barriers, natural antimicrobial 
products, immune cells, pattern-recognition receptors, 
and soluble products, cytokine and opsonins (e.g., com-
plement) are critical innate components. In this context, 
neutrophils and macrophages play an important role in 
induction either pro-inflammatory or anti-inflammatory 
responses into the inflammatory site [1, 2]. Thus, these 
cells are key components involved in the development 
of inflammatory responses of diverse pathological con-
ditions, such as chronic inflammatory diseases, infec-
tious disorders, autoimmunity and others diseases [3–5]. 
Autoimmunity reflects an imbalance between effectors 
and regulatory mechanisms, including the defective elim-
ination and/or control of innate and adaptive responses 
and the activation of cells with of varying subsets and 
phenotypes, such as macrophages and neutrophils, which 
release several products into tissue. Thus, this review 
highlights the role of macrophages subsets and neutro-
phils in the peripheral tissues, and also further support-
ing their cooperation during the development of the 
pathogenesis of T cell-mediated autoimmune disease, as 
type 1 diabetes mellitus and rheumatoid arthritis.
Macrophages and neutrophils: development 
and inflammation
Origin and development of neutrophils and macrophages
The first lines of defence against pathogens are the phago-
cytes cells, in which macrophages and neutrophils are 
included [6]. Neutrophils, the very short-lived human 
white blood cells (8–12 h in the circulation and 1–2 days 
in tissues), are the most abundant leukocytes in blood 
playing a primary role in the innate immunity [7]. These 
cells are produced in the bone marrow from multipo-
tential progenitor cells, under the action of numerous 
mediators in particular growth factors called granulocyte 
colony-stimulating factor (GCSF), which are the main 
regulator of the granulocytopoiesis as shown in Fig. 1 [8–
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known as myeloblast. The proliferation and differentiation 
of these progenitors and these cells depend on hematopoi-
etic cytokines such as GCSF, gene expression (responsible 
for the formation of granular proteins involved in cell 
function), myeloid transcription factors, forming the mye-
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Fig. 1 Origin and development of macrophages and neutrophils. a The generation of macrophages is dependent on hematopoietic growth factor 
receptor Csf1r (c-fms, M-CSFR, CD115). The known ligands of Csf1r, Csf1/M-CSF and interleukin (IL)-34 are likely both important for the develop-
ment of the mononuclear phagocyte lineage. On the other hand, hematopoietic cytokines as granulocyte–macrophage colony-stimulating factor 
(GM-CSF) and granulocyte colony stimulating factor (GCSF) that promote neutrophil progenitor proliferation and differentiation. b Bone marrow 
neutrophil lineage cells can be divided into three compartments: the stem cell pool (stem cells and pluripotent progenitors), the mitotic pool and 
the post-mitotic pool. c The regulation of Neutrophil egress from de bone marrow by CXCR4 and CXCR2 chemokine ligands, where stromal cells 
produce C-X-C-motif chemokine ligand (CXCL) 12 that binds to C-X-C-motif chemokine receptor (CXCR) 4, leading to neutrophil retention, while 
release is mainly mediated by CXCR2. Hematopoietic stem cell (HSC), common myeloid progenitor (CMP), granulocyte–macrophage progenitor 
(GMP), myeloid progenitor (MP)
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Thus, the GCSF acts by binding GCSF receptor, a fam-
ily member of the class I cytokine receptor, promoting 
the neutrophil’s population life cycle that includes its 
proliferation, differentiation, releasing of mature cells 
from the bone marrow and survival [9, 10, 13, 14]. In this 
context, the bone marrow neutrophil’s population can be 
distributed in the steam cell pool, the mitotic pool and 
the post-mitotic pool [10, 14]. The first to mature are 
the hematopoietic stem cells and pluripotent progeni-
tors; the next population, the mitotic pool, is composed 
of granulocytic progenitor cells such as myeloblasts, 
promyelocytes, and myelocytes. Lastly, mature neutro-
phils (metamyelocytes) are part of the post-mitotic pool, 
which constitutes the major source of neutrophils that 
can be easily mobilized and rapidly recruited to sites of 
infection [10, 14, 15].
All these populations are in homeostasis that includes 
a well-preserved equilibrium among granulopoiesis, 
bone marrow storage and release, intravascular transit, 
and destruction [14]. Therefore, after the neutrophil pro-
duction, development and storage in the bone marrow, 
its releasing includes a transcellular migration from the 
sinusoidal endothelium to the circulation [14, 16]. Then, 
among existing mechanisms, the chemokines and their 
receptors play a key role about the balance between neu-
trophil release and retention. The major role is played 
by the stromal derived factor-1 (SDF-1) produced in 
the bone marrow and its ligation with the C-X-C motif 
chemokine receptor (CXCR) types 2 and 4. While the 
interaction of SDF-1 with the CXCR2 leads to the release 
of neutrophils, the interaction with the CXCR4 produces 
the opposite effect, leading to the retention of the neutro-
phils in the post-mitotic pool (Fig. 1b) [10, 17, 18].
After the bloodstream, the neutrophil migrate into 
the tissues to perform its function. However, near the 
inflammatory lesions neutrophils adhere to the endothe-
lial wall, leave the blood vessels and actively migrate into 
the inflammatory focus [10]. This type of cells without 
external stimuli dies by apoptosis [12]. The process of 
cells death is a natural endpoint that occurs when the 
plasma membrane lose its integrity, or in the presence 
of cell fragments into discrete bodies and in the engulf-
ment of the cell by another [19, 20]. Thus, to maintain 
the immune homeostasis is necessary the clearance of 
the apoptotic neutrophils by macrophages [14, 15]. This 
process is called “efferocytosis” and involves the liver 
X receptor (LXR), the decreasing in the production of 
interleukin (IL)-23, IL-17 and GCSF, whereas its weak-
ened clearance has been associated with autoimmune 
diseases [10, 21, 22].
The other major defence against pathogens, inflam-
matory diseases and autoimmune diseases are the mac-
rophages [23]. This type of leukocyte has its origin in 
hematopoietic stem cell with a myeloid progenitor form-
ing the mononuclear phagocyte system (MPS) as shown 
in Fig. 1 [24]. Cytokines, as the macrophage-colony stim-
ulating factor (M-CSF) and hematopoietic growth factor 
receptor (Csf1) expressed in monocytes, macrophages, 
mononuclear phagocyte precursors, are the main regula-
tors of the MPS and both important for the development 
of phagocytic lineage [24, 25]. Therefore, MPS is consti-
tuted by monocytes, macrophages and dendritic cells 
(DC) [24]. Monocytes, precursor of tissue macrophages, 
are present in the bone marrow, circulation, and spleen, 
while the macrophages resides in lymphoid and non-lym-
phoid tissues [24]. However, recent studies suggest that 
many adult tissue macrophages have their origins during 
the embryogenic development, not only during the adult 
phase [26–28].
Thus, the embryonically derived macrophages are 
firstly detected and developed in the yolk sac being the 
only leukocyte produced independently of monocytes 
[29]. Afterward, all immune lineages forming the defini-
tive hematopoietic stem cells (HSCs) that migrate to the 
foetal liver [27]. The principal site of haematopoiesis just 
became the bone marrow in the perinatal period [30]. 
These embryonic—resident tissue macrophages along the 
adulthood loss the capacity to identify macrophage pop-
ulations [27]. Then, even with an origin dependent or not 
of monocytes, macrophages contribute to the homeosta-
sis of the immune system.
Activation of macrophages and neutrophils
In general, monocytes/macrophages contribute to the 
modulation of the immune response can lead to auto-
immunity. These cells are dynamic as to polarize phe-
notypes of pro-inflammatory and anti-inflammatory 
cytokines depending on the microenvironment, act-
ing with different physiological functions [31]. Recently, 
macrophages are subdivided in two main phenotypes: 
the classically activated macrophages (M1 macrophages) 
promote tissue inflammation and activated macrophages 
(M2 macrophages), these last is classified into three sub-
types according to their functions: host defence, tissue 
repair and immunoregulation [32] (Fig. 2).
Classically activated macrophages (M1 macrophages) 
intermediate host defence against a variety of bacte-
ria, protozoa and viruses and participate in anti-tumour 
immunity, autoimmune diseases [33, 34]. Lipopoly-
saccharides (LPS) as certain bacterial products and 
cytokines such as interferon (IFN)-γ stimulate mac-
rophages to M1 subset. As a result, M1 macrophages 
induce a strong pro-inflammatory phenotype with 
the production of cytokines (TNF-α, IL-6, IL-12 and 
IL-23) and chemokines (CCL-5, CXCL9, CXCL10 and 
CXCL5), promoting the recruitment of Th1 and Natural 
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killer (NK) cells. In addition, it has been shown that M1 
macrophages up-regulate the intracellular expression 
of a protein called suppressor of cytokine signalling 3 
(SOCS3), which increases the production of reactive 
oxygen intermediates and nitrogen, the expression of 
MHC class II molecules and costimulatory molecules 
[35, 36]. In this perspective, M1 macrophages promote 
Th1 immune responses, but also contribute to the tissue 
destruction and tumoricidal activity [37]. Therefore, an 
over-activation can lead to tissue damage such as occurs 
in various inflammatory, autoimmune and chronic dis-
eases, including Crohn’s disease, rheumatoid arthritis, 
diabetes, multiple sclerosis and autoimmune hepatitis 
[38–43].
Otherwise, alternatively activated macrophages (M2 
macrophages) are involved with immune regulation, tis-
sue remodelling, and elimination of parasites, tumour 
promotion and autoimmune diseases. The M2 mac-
rophages can be divided into three differing subpopula-
tions: M2a, M2b, and M2c macrophages [44–47]. They 
are clearly distinct, both functionally and biochemi-
cally [47]. In the context, macrophages contribute to the 
reparative extracellular matrix production, while regula-
tors macrophages express high levels of costimulatory 
Fig. 2 Schematic representation of macrophage activation and polarization. Classically polarized macrophages (M1 macrophages) are activated by 
LPS, IFN-ƴ and TNF-α. M1 cells have high microbicidal activity, immune-stimulatory functions and tumour cytotoxicity. Alternatively polarized mac-
rophages (M2 macrophages) are involved with anti-inflammatory, wound repair and tumour promotion. M2 macrophages can be further divide 
into M2a, M2b, and M2c macrophages. IL-4 and IL-13 always activate macrophages to be M2a, while M2b are activated by immune complexes 
(ICs), TLRs, or IL-1ra. Finally, M2c macrophages are polarized by IL-10, TGF-β or glucocorticoids. All of the phenotypes express a series of different 
cytokines, chemokines and receptors
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molecules (CD80 and CD86) and can present antigen to 
T-cells, although, there are differences among the sub-
types M2 macrophages, usually macrophages repairers 
and regulators exhibit immunosuppressive activity [48].
The M2a macrophage is stimulated by IL-4/IL-13 
through the binding of these cytokines to their receptors, 
which then activates STAT-6 signalling pathway. It also 
up regulates the histone demethylase JMJD3, by alter-
ing of chromatin modifications that induces expression 
of M2 gene and inhibits M1 gene during tissue repair 
and anti-inflammatory response [49, 50]. In addition, 
M2a macrophages up-regulated the Mrc1, resistin-like 
a (Retnla, Fizz1) and chitinase 3-like 3 (Chi3l3, Ym1) 
expression, suggesting that these expressions are selec-
tive markers of M2a macrophages [51].
M2b macrophages are polarized by combined immune 
complexes that contain toll-like receptor (TLR) and/or 
IL-1 receptor agonists [35, 52] and produce high levels 
of pro-inflammatory cytokines, including IL-1, IL-6 and 
TNF [53]. M2a macrophages also induce the influx of 
eosinophils, basophils, Th2 cells and regulatory T-cells by 
secreting CCL24, CCL17, CCL1 and CCR1 at the site of 
inflammation [54].
The M2c macrophages are induced by transforming 
growth factor (TGF)-β, glucocorticoids [37] or IL-10. In 
this context, IL-10 is secreted by dendritic cells, B cells, 
cytotoxic T-cells, T-cells, NK cells, mast cells, neutro-
phils, eosinophils, as well as monocytes/macrophages 
[55]. The activation mediated by IL-10 acts through 
a transmembrane receptor complex composed of IL-
10R1 and IL-10R2. Thus, the IL-10/IL-10R1 interaction 
changes the cytokine conformation leading to its dimeri-
zation with IL-10R2, which activate Jak1/STAT3 signal-
ling pathways [55].
These macrophages are engaged in a complex bidirec-
tional interaction with neutrophils. They also can drive 
the development of the innate and acquired immune 
responses by complicated cross-talk with other cells, 
including natural killer and DC [56]. Various mecha-
nisms underlying the neutrophils’ antimicrobial activ-
ity, such as phagocytosis, generation of reactive oxygen 
species (ROS), cytokines, chemokines, lipid mediators, 
degranulation of antimicrobials and enzymes [57]. In 
2004, Brinkman et  al. [17] demonstrated that neutro-
phils generate an extracellular chromatin fibre, called 
neutrophil extracellular traps (NETs), which disarm and 
kill extracellular bacteria [58]. The NETs are composed 
of DNA, histones, amphotericin HMGB1 (high-mobil-
ity group box 1), and globular structures that consist in 
components granules of neutrophils, such as neutrophil 
elastase (NE), myeloperoxidase (MPO), cathepsin G, pro-
teinase 3, cationic bactericidal permeability increasing 
protein (BPI), calgranulin, α-defensins, lactoferrin, the 
peptide LL-37, pentraxin PTX3, matrix metalloprotein-
ase-9 (MMP-9) and peptidoglycan recognition protein-S 
(PGRP-S) [59–61].
The mechanisms involved in the NETs formation 
are not fully elucidated. It was demonstrated that upon 
activation (by lipopolysaccharide, bacteria, fungi), neu-
trophils start a programmer that leads to their death by 
a mechanism distinct of apoptosis and necrosis, called 
NETosis [62]. For this, NE translocates to the nucleus, 
where it breaks, partially, specific histones, promoting 
chromatin decondensation [63], and the nuclei of neutro-
phils lose their shape, and heterochromatin homogenize 
[15]. The chromatin decondensation is made by the MPO 
enzyme, probably, due to the synthesis of hypochlorous 
acid [63]. Moreover, NETs formation depends on the 
ROS production by NADPH oxidase [22]. This ROS may 
alter several macromolecules, including DNA, proteins 
and lipids, making them more susceptible to attack by 
neutrophil enzymes [64]. In addition, the peptidyl argi-
nine deiminase 4 (PAD4) induced catalyzes deamination 
of arginine residues in the histones intensifying chroma-
tin decondensation [65, 66]. Finally, the nuclear envelope 
and the granule membranes disintegrate, allowing the 
mixing of NET components, then NETs are released as 
the cell membrane breaks [67].
Initially, the formation of NETs was considered an 
innate immune response in response to infections. How-
ever, recent evidence suggests that these structures are 
involved in the pathogenesis of various diseases, includ-
ing autoimmune disorders [62–65]. Regarding to auto-
immunity, the molecules present in the NETs or the 
degradation products of NETs by DNAse I can act as 
auto-antigen [63, 64]. Several groups have proposed that 
the excessive formation or degradation failure of NETs 
that lead to the expression of a set of auto-antigens and 
danger-associated molecular patterns, are important fac-
tors in the development of autoimmune responses in pre-
disposed individuals, as shown in Fig. 3 [62–66].
The role of macrophages and neutrophils in the innate 
and adaptive immunity
Macrophages and neutrophils are qualified phagocytes 
that correspond to the first lines of defence against patho-
gens [68]. In general, the neutrophils were associated with 
acute inflammation, while monocyte/macrophages appear 
to be associated the chronic inflammation [69]. However, 
several studies have challenged these dogmas, showing 
that neutrophil is a key effector cell in the orchestration of 
the adaptive immunity in the resolution of chronic inflam-
matory response [70–72], while monocytes/macrophages 
are important in acute inflammation [73]. In this regards, 
neutrophils are the first leukocytes that are recruited rap-
idly into acute infection site, which after their activation, 
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they kill or phagocytosis foreign bodies and release solu-
ble mediators, as cytokines that induce the recruitment of 
monocytes to the inflammation site [69, 74, 75]. On this 
occasion, monocytes would then be recruited following 
neutrophils to the site of injury and differentiate into mac-
rophages [1]. Certain studies suggested a predominance 
of monocytes/macrophages that substitutes the neutro-
phils. This propose a bimodal recruitment pattern that 
interchange neutrophils to monocytes [76]. However, cur-
rently there is evidence that chemoattractant, as MCP-1, 
produced in  situ by tissue monocytes/macrophages rap-
idly and directly induces the monocytes influx regardless 
of the presence of infiltrating neutrophils at inflammation 
site [1]. Thus, neutrophils and monocytes found into the 
inflammatory site can participate in both the innate and 
adaptive immune response, displaying several functions 
described in Table 1.
In this context, monocytes ∕ macrophages play a cen-
tral role in both adaptive and innate immunity, due these 
cells play dual role in tissue injury, either injury-inducing 
or repair-promoting [73]. Thus, macrophages constitute 
an important class of antigen-presenting cells (APC) 
that activate adaptive immunity, as well act in phagocy-
tosis, antigen processing and presentation, leading to 
the activation of T and B cells. These cells also secrete 
pro-inflammatory, anti-inflammatory, angiogenic, fibro-
genic or mitogenic cytokines. These processes cooper-
ate with others immune and progenitor cells to control 
the initiation, resolution, and repair tissue damage dur-
ing chronic inflammation [73, 77]. In summary, this cell 
has a large repertoire of well-characterized abilities and 
functions both in innate and adaptive immunity, includ-
ing regulation of inflammatory responses, stimulation 
of T and B cells, may promote Th1 cells differentiation, 
Fig. 3 Neutrophil extracellular traps. Neutrophil extracellular traps (NETs) are composed of nuclear components (such as DNA and histones) and are 
decorated by proteins from primary granules (such as myeloperoxidase and neutrophil elastase), secondary granules (such as lactoferrin and pen-
traxin 3), and tertiary granules. NETs have been shown to trap microorganisms. Initially, the neutrophils become rounded with uniformly condensed 
chromatin, occurs because of PAD-4-mediated citrullination of histones, and then undergo nuclear envelope breakdown so DNA-containing 
vesicles eventually fuse with the plasma membrane, and NETs are released to trap microorganism. NETs can cause development of autoimmune 
disorders trough molecules present in the NET or the degradation products of NETs by DNAse I can act as auto-antigen or because excessive forma-
tion of degradation failure of NETs. Font: Adapted by [71], Mantovani et al. [72] and Phillipson and Kubes [245]
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tissues homeostasis and development, repair of damaged 
tissue, rejection of a xenograft, induce angiogenesis and 
lymphangiogenesis, modulation of osteoclastogenesis, as 
well as macrophages are key component in elimination 
of pathogens and removal of dying cells by efferocyto-
sis [5, 78–80]. In addition, resident tissue macrophages 
also are patrollers in epithelial tissues, ensuring the entry 
and colonization sites for pathogens in order to prevent 
the invasion of these infectious agents [80]. An impor-
tant example is the alveolar macrophages, which keep 
the lung surface under surveillance-inhaled pathogens 
[5]. In adaptive immunity, recent studies reported that 
macrophages may control the effector T-cell homeosta-
sis, promoting the T-cell priming and also inducing Th17 
cell differentiation [81]. Also, macrophages modulate 
cytokine release and T-cell activation, resulting in neuro-
pathic pain [82].
After injury, with or without infection, neutrophils 
recruited into tissue have an anti-infectious and pro-
inflammatory function, due to their ability to phagocyte 
and to produce powerful components for the host, i.e., 
ROS, such as O2−, H2O2, HOCl, and ·OH; antimicro-
bial peptides, proteolytic enzymes as serine proteases 
and metalloproteinase; and release NETs, leading to tis-
sue injury [83–85]. However, recruited neutrophils are 
mostly removed by DC and macrophages at the site of 
inflammation by a process of cell corpse removal called 
efferocytosis [86].
Even though neutrophils are the hallmark effector 
cells of acute inflammation, these cells also contribute to 
chronic inflammation and adaptive immune responses, 
such as cytokines (as IL-17) secreted from neutrophils 
regulate the immunity by inducing the expression of 
pro-inflammatory factors (such as cytokines, chemokines 
and MMPs) from mesenchymal and myeloid cells, lead-
ing to the perpetuation of the recruitment and activation 
of additional neutrophils in chronic inflammation [87]. In 
addition, neutrophils directly interact with macrophages, 
DC, and lymphocyte subsets and modulate their effector 
functions; as well as promote the maturation of human 
monocyte-derived DC (moDC) [88]. They interact with 
DC leading to activation of NK cells and communicate 
with the B and T-cells and NK cells, as well as cross-
interact with NK cells that produce IFN-γ, which pro-
motes survival and activation of the neutrophil [87, 89, 
90]. Thus, activated neutrophils secrete chemoattract-
ant, such as CCL2, and CXCL10 or CCL2 and CCL20, 
which attract and recruit Th1 and Th17 cells, respectively 
[91, 92]. Neutrophils may express MHC II class and act 
as APC, thus it migrates to the lymph node attracted to 
CCR7 [93–95]. Furthermore, the neutrophils can also 
present exogenous antigens via MHC I class, promoting 
the differentiation of naive CD8+ T-cells into cytotoxic 
T-cells [95]. On the other hand, neutrophils can also 
compete with the professional APC and thus inhibits the 
T CD4+ response [95, 96].
Due the ability of neutrophils and macrophages to initi-
ate and control the immune responses against invading 
pathogens as well as against self-proteins derived pep-
tides, thereby they play an important role in the patho-
genesis of autoimmune disorders, such as autoimmune 
diabetes, rheumatoid arthritis and Systemic Lupus Ery-
thematosus (SLE). However, the nature of the contribu-
tion of these cells in autoimmune disorders is not yet 
fully elucidated, but there are several important factors 
affecting on the immunogenicity of these cells, including 
Table 1 General functions of macrophages and neutrophils in innate and adaptive immunity
IFN-γ: interferon gamma; TNF-α: tumour necrosis factor-α; IL-1β: interleukin-β; GCSF: Granulocyte colony-stimulating factor; GM-CSF: Granulocyte macrophage-colony 
stimulating factor; MIP-1α: macrophage inflammatory protein-1α; NETs: Neutrophil extracellular traps
Monocyte/macrophage Neutrophil
Innate immunity Opsonic recognition [229]
Production of pro-inflammatory and anti-inflammatory 
cytokines [230]
Release GCSF and GM-CSF [231]
Excessive release of toxic species (NO, superoxide and MMP) 
[232]
Antigen processing, and presentation [233]
Production of prostaglandins, leukotrienes and proteases [234]
Release MIP-1α and MIP-1β [235]
Release cytokines, such as IFN-γ, IL-8 and TNF-α [71]
Secretion of antimicrobial molecules [236]
Phagocytosis [237]
Release lytic enzymes and producer active oxygen intermedi-
ates [71]
Release neutrophil extracellular traps (NETs) [71]
Adaptive immunity Secretion of hydrolytic enzymes [238]
Cleavage of C3 [239]
Induce neovascularization and contribute to angiogenesis and 
lymphangiogenesis [240]
Modulate the osteoclastogenesis [241]
Efferocytosis [242]
May induce Th1 cells differentiation [78]
Control the effector T-cell homeostasis, promoting the T-cell 
priming and also may induce Th17 cell differentiation [81]
Release IL-17 [243]
Release NETs [71]
Promote the maturation of human monocyte-derived DC [88]
Chemotaxis of Th1 and Th17 [59, 60]
Differentiation of naïve CD8+ T-cells [244]
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the type and dose of antigen, the microenvironment of 
the cell-antigen encounter, the number, the subset, and 
phenotype of these cells, which can prevent or induce 
autoimmune responses. In this regard, Orme and Moah 
[6] reported important alterations of these cells during 
the establishment of SLE such as: (1) enhanced apopto-
sis; (2) enhanced chemotaxis due the overexpression of 
MCP-1, MIP-1α, CCL5, CXCR4, CXCL12; (3) impaired 
phagocytosis related to high levels of the comple-
ment receptor CR3 (CD11b/ITGAM) and of FCγR1; (4) 
impaired immune—complex clearance; (5) and impaired 
superoxide production.
Overall, most studies indicate that adaptive immu-
nity alone is involved in autoimmune disease. However, 
other studies have suggested crosstalk between cellu-
lar and humoral components involved in the innate and 
adaptive immune systems, which indicates that the loss 
of the immune homeostasis between two important pro-
inflammatory and anti-inflammatory effectors may trig-
ger the effector phase of autoimmune diseases, as shown 
in Fig. 4 [97, 98].
Crosstalk between neutrophils/macrophages 
in autoimmune type 1 diabetes
Autoimmune type 1 diabetes mellitus (T1DM) is a seri-
ous chronic autoimmune disease characterized by an 
absolute insulin deficiency, resulting from an depletion 
of insulin-secreting β cells located in pancreatic Langer-
hans’ islets mediated by autoantigen-specific CD4(+) and 
CD8(+) T-lymphocytes promoting further inflammation 
in this tissue [99–101]. In this regard, innate immune 
cells such as γδT-cells, NKT, macrophages and neutro-
phils play essential roles in the pathogenesis of T1DM 
[102]. These cells produce cytokines that promote β-cell 
apoptosis and increase infiltration of islet specific T-cells, 
then this T-cells attack and destroy β-cells, resulting in an 
insulin deficiency [102].
A lack of insulin results in an inability to regulate blood 
glucose effectively, leading to chronic hyperglycaemia. 
Therefore, T1DM may provide a state of hypoinsulinemia 
and hyperglycaemia, and causes serious health complica-
tions including ketoacidosis, kidney failure, heart disease, 
stroke, and blindness [103]. In diabetes cases, approxi-
mately 5–10% of diabetics have T1DM [104], which 
can be classified into two categories: Type 1A diabetes 
mellitus, resultant of an autoimmune response destroy-
ing the β-cells, while type 1B is an idiopathic destruc-
tion of the β-cells [104]. Type 1A diabetes mellitus has 
a predominantly genetic origin, there are at least 15 loci 
associated with T1DM, mainly polymorphic genes, such 
as the human leukocyte antigen (HLA) loci, interleukin 
2 receptor alpha (IL2R2), insulin-variable number tan-
dem repeat (VNTR), vitamin D receptor (VDR), cyto-
toxic T-lymphocyte-associated protein (CTLA)-4 genes 
[102, 105, 106]. For example, HLA class II haplotypes 
either DR3DQ2 or DR4DQ8 are express in more than 
90% of patients with T1DM [107]. In general, the trig-
gers that initiate the immune-mediated destruction of 
the β-cells include viruses (Coxsackie B viruses, rubella 
viruses, cytomegaloviruses and retroviruses), dietary fac-
tors (cow’s milk, plant proteins, nitrates, wheat gluten) 
and other environmental factors (e.g., caesarean delivery, 
Fig. 4 Major mechanism of action of neutrophils and macrophages in type 1 diabetes and rheumatoid arthritis
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early childhood diet, vaccines and use of antibiotics), as 
well as gut microbes [102, 108].
In addition, hyperglycaemia may be a trigger to inflam-
matory response in T1DM, because it may increase the 
levels of circulating C-reactive protein (CRP), free fatty 
acids, CXCL-8, and pro-inflammatory cytokines, such as 
IL-6, IL-1β and TNF-α [109–111]. Hyperglycaemic con-
ditions can also facilitate the activation of human T-lym-
phocytes [111, 112]. Therefore, the innate immunity plays 
a critical role in T1DM, because various cells, including 
macrophages, dendritic cells, NK cells and neutrophils, 
may recognize pathogens and foreign molecules with-
out having been previously exposed to them and without 
generating long-term immune response [102].
In acute inflammation, macrophages, mainly the M1 
macrophages, are first cells accumulate at one side of 
the pancreatic islet at an early stage (2–3 weeks of age), 
along with neutrophils, dendritic cells (DCs) and B 
lymphocytes [113]. In this regard, M1 macrophages can 
trigger an inflammation and initiate pancreatic β-cell 
death and insulitis during type 1 diabetes [114, 115], as 
well as it contributes to prolongation of inflammation 
instead of its resolution [114]. The M1 macrophages are 
pro-inflammatory cells that responds to intracellular 
pathogens producers of TNF-α and interleukins (IL-
1β, IL-6, IL-8, IL-12, and IL-23), express costimulatory 
molecules important in T-cell activation (MHC, CD40, 
CD86), and produce proteases (leucocyte elastase, and 
matrix metalloproteinases), such as NO through the 
expression of iNOS and ROS [116]. Therefore, ROS 
can induce apoptosis or necrosis of β cells by activat-
ing the caspase pathway and inducing excessive cell 
stress, respectively, because this cell is very sensitive to 
free radicals and has low free radical scavenging activ-
ity [116, 117].
During the chronic inflammation, the IL-12 from M1 
macrophages can contribute to destruction of β cells 
in T1D by directing the development of Th1 cells, with 
the involvement of CD4+ and CD8+ lymphocytes [118, 
119]. Furthermore, activated M1 macrophages have 
an enhanced ability to present antigen and then stimu-
late the activation of CD8+ T-lymphocytes, which are 
directly involved in the destruction of pancreatic β-cells 
[115, 116, 120]. In animal model, certain studies also 
pointed to the evidence for initial involvement of mac-
rophage in development of insulitis in non-obese diabetic 
(NOD) mice [121, 122]. Other study showed in NOD 
mice that macrophages from pancreas produced more IL 
1β than peritoneal macrophages [123]. This cytokine pro-
duction mediates the damage outcome of macrophages 
on β-cells [124].
However, both macrophages M1 and M2 phenotypes 
play central role in diabetes.
Similarly, the M2 macrophages phenotypes have also 
been reported for NOD mice [120, 125] and in human 
T1D [126, 127]. However, M2 macrophages have distinct 
functions of M1 macrophages, because the M2 mac-
rophages decrease hyperglycaemia, insulitis and inflam-
mation in the pancreas [116]. In this regard, the adoptive 
transfer of immunomodulatory M2 macrophages pre-
vents type 1 diabetes in NOD mice [128]. In short, the 
characterization of subpopulations of macrophages in 
diabetes may be useful in designing new strategies to 
T1DM understanding. Several evidence reported that 
M2 macrophages secretes anti-inflammatory cytokines 
IL-4/IL-13 and expresses high levels of PD-1 ligands 
(Program-Death 1), PDL-1 and PDL-2, thereby this 
mechanism may inhibit the proliferative response of acti-
vated T-cells in T1DM [116].
Regarding to neutrophils, Battaglia [100] highlighted 
that these cells are crucial in the initiation and perpetu-
ation of T1DM, during acute and chronic inflammation, 
by two proposed mechanisms: (1) one is due the pro-
duction of pro-inflammatory cytokines, as IL-17, which 
promote granulopoiesis and consequent neutrophil pro-
liferation and accumulation, leading to prejudice pan-
creatic cells; and (2) another involves the unintended 
entrance of bacteria on pancreas that release toxins, 
leading to the production of IL-6 and IL-8 that attract 
neutrophils. Therefore, immune cells in pancreas, espe-
cially macrophages and neutrophils are responsible to 
the initiation and perpetuation of T1DM. Other study 
reported by Huang et al. [56], showed that several indica-
tions suggest the involvement of neutrophils in the initia-
tion and perpetuation of autoimmune diabetes, such as 
an increased numbers of neutrophils in blood of type 1 
diabetes patients, activation and recruitment of neutro-
phils to pancreatic islets in T1DM patients, liberation of 
neutrophil toxic mediators and the antineutrophil treat-
ments were able to reduce the insulitis and autoimmune 
diabetes.
In this context, in diabetic ketoacidosis patients (DKA) 
have been found monocytosis and neutrophilia in dif-
ferential white blood cell count, consistent with previ-
ous reports of increased circulation of leukocytes during 
DKA [129]. Although, there are controversies regarding 
the exact roles of neutrophils, this cell was found in the 
pancreas of patients with T1DM, both at the onset and at 
later stages of the autoimmune process [130]. Some stud-
ies have shown an increased adherence of neutrophils to 
the cerebrovascular endothelium in diabetic ketoacidosis 
patients [109, 131]. In diabetic ketoacidosis patients were 
found activated neutrophil with high release of toxic 
granule content in serum, as elastase, proteinase-3 and 
myeloperoxidase [132]. Also, patients with T1DM had 
markedly elevated levels of NE and proteinase 3 (PR3), 
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which are serine proteases stored in neutrophil primary 
granules [133]. On the other hand, other studies reported 
that neutrophils from insulin-dependent diabetics dis-
play diminished levels of oxygen radicals (O−
2
) and acti-
vation of phospholipase D in response to FMLP, which 
was attributed to the high glucose concentration in these 
patients [134]. Also, certain studies have shown that cir-
culating neutrophil number was decreased in patients 
with T1DM, which may associated with abnormal neu-
trophil yield and maturation, peripheral consumption or 
damage, and tissue detainment [130, 135].
In animal studies, Alba-Loureiro et al. [136] showed that 
neutrophils from diabetic rats exhibited decreased phagocy-
tosis and phorbol myristate acetate (PMA)-stimulated H2O2 
production. Similarly, Nurun Nabi et  al. [137] reported 
that neutrophils from diabetic rats were more activated at 
their basal level, though it exhibited lower morphologi-
cal polarization in response to FMLP. These authors also 
demonstrated that in increased plasma glucose level can 
reduce the phagocytosis of neutrophils from diabetic rats 
[137]. In addition, Diana et  al. [138] observed the occur-
rence of neutrophils inside the pancreatic infiltrate of NOD 
mice, but not in non-autoimmune C57BL/6 and BALB/c 
mice [138]. Another study in NOD mice showed that one 
of the chemokine receptor that regulates the trafficking of 
neutrophils to pancreas is the CXCR2, which ligands are 
produced by pro-IL-1β secreted by pancreatic macrophages 
[123]. Thus, the role of neutrophils in T1D started to be elu-
cidated. The presence of neutrophils that secrets cathelici-
din-related antimicrobial peptide (CRAMP) was observed 
in NOD mice histological analysis [138]. In others autoim-
mune diseases, CRAMP’s stimulates the plasmacytoid den-
dritic cells (pDCs) to produce IFN-α. Therefore, immune 
cells in pancreas, especially macrophages and neutrophils 
are responsible to the initiation of T1D.
Together, the current findings indicate that high levels 
of chemokines, such as CXCL1/KC (or human IL-8) and 
MCP-1/CCL2, are secreted into the pancreas during the 
T1DM. These chemokines play a key role in the recruit-
ment of neutrophil and macrophages/monocytes, respec-
tively, from the blood vessels to the pancreatic islets 
[139–141]. In this regard, as shown above, human and 
animal studies showed that macrophages and neutrophils 
were found to infiltrate islet of young NOD mice and 
T1DM patients, and the inhibition of influx these cells 
into the pancreas, by depletion or inhibiting their adhe-
sion molecules, prevents the development of insulitis 
and inflammation in T1DM [114, 130, 142–144]. These 
facts, taken together, suggest that macrophages are cells 
important in stimulation of the influx and activation of 
cells, including T-cells, which lead to destruction of the β 
cells. After started the inflammatory process, other cells 
are recruited to the pancreas, such as neutrophils, which 
at the beginning of the pathology are involved in the 
propagation of tissue damage through the release of toxic 
chemicals. Thus, these findings support the evidence for 
a crosstalk between macrophages and neutrophils that 
participate in closely in the inflammatory response and 
progression of the initial pancreatic damage in T1DM.
Crosstalk between neutrophils/macrophages 
in rheumatoid arthritis
Rheumatoid arthritis (RA) is an inflammatory autoim-
mune disease characterized as a chronic inflammation 
within the synovial tissues in multiple joints (synovitis), 
leading to progressive and erosive destruction of cartilage 
and joints, and the underlying bones [145]. The pannus 
formation and synovial hyperplasia are the main features 
of RA, due an abundant cellular infiltrates of several cell 
types (neutrophils, macrophages, fibroblasts, T-cells, and 
dendritic cells) in the synovial [146, 147]. Furthermore, 
aetiology and pathogenesis of RA have not been com-
pletely elucidated, but it is widely accepted that is a mul-
tifactorial disease associated with genetic factors (HLA 
genes, as HLA-DRw4 and HLA-DRB1, PTPN22 (encod-
ing tyrosine-protein phosphatase non-receptor type 22) 
gene, protein-arginine deiminase type 4 (PADI4) gene 
and cytotoxic T-lymphocyte protein 4 (CTLA-4) gene), 
environmental (e.g., cigarette smoke), gender and age 
[148–150]. In this context, certain studies report poten-
tial roles for sex hormones and sex chromosomes in 
induction of RA [151, 152].
Furthermore, environmental factors may lead molecu-
lar changes to host proteins, followed by breakdown of 
immune tolerance to self, thereby increase the risk of 
developing RA in individuals with genetic risk factors 
[153]. Certain environmental exposures induce peptidyl 
arginine deiminase (PAD) enzyme activation and conse-
quently protein citrullination [154, 155] that in turn lead 
to development of autoantibodies to citrullinated protein 
antigens (ACPAs), which are detected in RA patients 
serum [156]. ACPAs are directed against different cit-
rullinated antigens, including fibrinogen, fibronectin, 
α-enolase, collagen type II, histones. Furthermore, these 
antibodies are detected years before the onset clinical 
arthritis and are associated with joint radiographic dam-
age and extra-articular manifestations [157]. In the RA, 
there are many cell types that play a role in the pathogen-
esis, such as fibroblasts, T-lymphocytes, B lymphocytes, 
neutrophils and macrophages [158]. It is known that 
there is an imbalance between pro and anti-inflammatory 
cytokines that can be a key mechanism underlying dis-
ease progression in collagen-induced arthritis (CIA) mice 
model as well as in human RA [159].
In this context, neutrophils are the first effector cells 
at the site of inflammation, mainly in the initiation of 
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various pathologies including chronic inflammatory 
diseases. Thereby, these cells play a key role in the tis-
sue damage and facilitate the inflammatory process in 
RA, leading to joint destruction in arthritis models [160, 
161]. In animal models studies, the neutrophil deple-
tion with antibodies blocked or reversed the joint swell-
ing and joint inflammation in arthritis [162]. In addition, 
neutrophils are the most abundant both in the synovial 
fluid (SF) and pannus of patients with active RA. Che-
moattractants such as GCSF and IL-8 stimulate neu-
trophil migration from the peripheral blood to the joint 
in RA [163], as well as promotes neutrophil trafficking 
into inflamed joints [164]. In this context, some studies 
showed that neutrophils from RA patients are function-
ally different from those of healthy individuals, because 
they have delayed apoptosis and are more susceptible to 
stimulation via TLRs and receptors for complement frag-
ments, growth factors, cytokines and immune complexes 
[165–168].
Once activated, in acute inflammation of RA, neutro-
phils release high concentrations of oxidants and cyto-
toxic products, such as ROS, cytokine (such as TNF-α) 
and granules containing proteases, phospholipases, 
defensins and myeloperoxidase, in the synovial fluid or 
directly onto the surface of articular cartilage [166, 167, 
169]. Moreover, Wright et al. [156] summarized the rel-
evant role of certain neutrophil granule enzymes found 
in high concentrations in RA synovial fluid, such as con-
tributes to the destruction of the articular cartilage and 
tissue (e.g., elastase, gelatinase and collagenase), pro-
motes inflammation and activate cytokines/receptors 
(e.g., elastase, cathepsin G, proteinase 3 and lactoferrin), 
as well as inhibits resolution of chronic inflammation and 
cartilage repair (e.g., myeloperoxidase and gelatinase-
associated lipocalin). In addition, other effects also were 
described, including inhibit chondrocyte apoptosis (e.g., 
lactoferrin), and regulating migration, invasion and pro-
liferation of synoviocytes (e.g., cathepsin and matrix met-
alloproteinases) [170–176].
In chronic inflammation of RA, several studies have 
linked neutrophil functions to Th17 cells. These cells are 
producers of IL-17 that is a potent pro-inflammatory 
mediator implicated in the pathogenesis of RA, involved 
in induction of tissue inflammation by stimulating the 
recruitment of neutrophils. In the RA joint, IL-17 also 
activates fibro-blast-like synoviocytes, macrophages, and 
osteoblasts [91, 92, 177]. Thus, these activated cells in 
the joint produce potent neutrophil chemoattractants, as 
IL-8 and TNF-α, which in combination with IL-17 stim-
ulate synovial endothelial cells to produce more neutro-
phil chemoattractants [91, 92, 177]. Thereby, neutrophils 
found in the RA joint help sustain Th17 cells through the 
secretion of Th17 chemokines, as CCL20 and CCL2 [91, 
92]. In addition, synovial fluid and peripheral blood neu-
trophils from patients with osteoarthritis are more likely 
to form NETs than in neutrophils from healthy controls 
[177]. In this regard, NETs also are source of citrullinated 
protein, as such histone and vimentin, because during 
NETosis occurs hypercitrullination of histones induced 
by the enzyme peptidyl arginine deiminase type 4 (PAD4) 
[178]. The ACPAs in the serum of patients with RA react 
with histone H4 in the NETs [179] and are correlated with 
disease activity and the severity of joint destruction [153]. 
Indeed, RA serum, anti-antibodies, as well as inflamma-
tory cytokines IL17A and TNF, induce NETosis in RA 
neutrophils [180]. Overexpression of IL-17A in healthy 
mouse knee joints induced rheumatoid arthritis (RA)-
like pathology with features including joint inflammation, 
focal bone erosion and cartilage damage [181]. In fact, 
NETosis is enhanced in circulating and synovial fluid neu-
trophils from patients with RA and it was observed NETs 
infiltrated in RA synovial tissue, rheumatoid nodules, and 
skin, mainly in patients with high levels of ACPA. In addi-
tion, NETs enhance inflammatory responses in RA syno-
vial fibroblasts by stimulating production of IL-8 that may 
further enhance NETosis [182], citrullinated autoantigen 
exposure, and promote autoantibody generation ampli-
fying mechanism of joint damage [183]. In conclusion, 
NETs externalize various immunostimulatory molecules 
and citrullinated auto 1 antigens that, in predisposed indi-
viduals might account for persistent generation of ACPA.
Therefore, in summary, there is strong evidence that 
the neutrophils have multiple functions in regulating 
acute and chronic inflammation in RA, such as: (1) pro-
duce mediators, such as IL-10, IL-1 receptor antagonist 
(IL-1ra) and TGF-β, with play an important anti-inflam-
matory role during both acute and chronic microbial 
infections or that contribute to resolution of inflamma-
tion; (2) secrete pro-inflammatory and anti-inflammatory 
cytokines and chemokines that regulate the function of 
immune cells (e.g., active macrophages, promote activa-
tion, proliferation and differentiation of T-lymphocytes, 
recruitment and maturation of dendritic cells) [156, 184, 
185]; (3) Human neutrophils express MHC class II (HLA-
DR) and co-stimulatory molecules (e.g., CD80 and CD86) 
that stimulate superantigen-dependent T-lymphocytes 
activation, as well promote differentiation of the Th1 and 
Th17 effector T-cell subsets [94, 186–188]; (4) Activated 
neutrophils express the B cell–activating cytokine (BLyS 
or BAFF) and the interaction between neutrophils and 
marginal zone B cells mediate T-cell–independent anti-
body responses through BAFF and a proliferation-induc-
ing ligand (APRIL) [189–193]; (5) Neutrophils play a role 
in regulating the homeostasis; terminal differentiation 
and functional responsiveness of NK cells in human and 
mice, as well as neutrophil-derived mediators modulate 
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NK cell effector functions, possibly in close relationship 
with dendritic cells [88, 156, 193]. Other functions also 
were reported, as synovial fluid neutrophils of patients 
with exacerbation of RA strongly express receptor activa-
tor of nuclear factor kappa-B ligand (RANKL) that acti-
vate the osteoclastogenesis [166, 194], while peripheral 
blood neutrophils from both RA patients express B lym-
phocyte stimulator (BLyS or BAFF), which is implicated 
in regulation of B cell-dependent autoimmunity [195].
Macrophages are one of the resident cell types in syn-
ovial tissue, along with fibroblasts [196]. In the context, 
once activated macrophages have a critical role in RA in 
chronic inflammatory arthritis and these cells have high 
plasticity, differentiating into different phenotypes, which 
can secrete either pro-inflammatory (M1 macrophages) 
or anti-inflammatory (M2 macrophages) cytokines [46, 
197]. Both macrophages types are important to medi-
ate matrix destruction or deposition, as well as help to 
resolution of inflammation [44, 196, 198]. During the last 
years, several studies have found greater numbers of M1 
macrophages in synovial membranes of patients with RA 
and its depletion using specific antibodies can prevent 
their presence in the pannus and thus attenuate inflam-
mation [199–201]. In addition, monocytes/macrophages 
are also associated with pathological bone erosion on 
RA, because these cells differentiate into osteoclasts, spe-
cialized cells in bone resorption [202].
Overall, synovial macrophages may stimulate the 
angiogenesis, leukocyte and lymphocyte recruitment, 
fibroblast proliferation, and protease secretion lead-
ing to eventual joint destruction [203–205]. M1 mac-
rophages have around 30–40% of the cellular content, 
and secrete pro-inflammatory cytokines (TNFα, IL-1, 
IL-6, IL-12, IL-23, and low levels of IL-10) and enzymes 
involved in driving the acute inflammatory response and 
joint destruction [196]. In addition, high levels of pro-
inflammatory cytokines and chemokines also contribute 
to the cartilage and bone destruction, and in the pan-
nus formation in RA [119]. In this context, chemokines 
released by M1 macrophages promote the recruitment 
of leukocytes to the inflamed joint, which produce more 
pro-inflammatory mediators as IL-1, TNF-α IL-6 and 
matrix metalloproteinase leading a destructive poten-
tial synovial and bone, mainly in osteoarthritis [147]. 
Therefore, the IL-1 and TNF-α are the most abundant 
cytokines in the inflamed synovium, leading to syno-
vial inflammation and activate chondrocytes and syno-
vial fibroblasts. Thus, these cells produce IL-6, IL-8, and 
leukocyte inhibitory factor, as well as stimulate protease 
and prostaglandin production in synovia [206–208]. 
In addition, IL-1 and TNF-α also induce the expres-
sion of other cytokines (e.g., IFNγ), cell-adhesion mol-
ecules, chemokines and chemokine receptors, antigenic 
factors and lipid mediators and inducible nitric oxide 
synthase (iNOS) in the inflammatory site [41, 196]. 
The TNFα and other molecules also induce the histone 
acetyltransferase (HAT) activity in macrophages, lead-
ing the acetylation of histones and subsequent modula-
tion of transcriptional factors [196]. The IFNγ is another 
cytokine highly expressed in RA synovial tissue and its 
elevated levels correlates with RA severity [209]. In this 
context, pro-inflammatory cytokines, like TNFα, can 
upregulate the production of INFγ that increase the 
response of M1 macrophages, while IL-10, anti-inflam-
matory cytokines downregulate this effect [210, 211]. 
Therefore, Wallet et  al. [211] showed that IFNγ-primed 
activated macrophages produced elevated levels of TNFα 
and other TH1 cytokines, as IL-12p70, but not of regula-
tory cytokine, as IL-10. Regarding to IL-10, Ji et al. [212] 
reported that in RA occurs a suppression of IL-10 sig-
nal transduction by blocking the FCγ receptor ligation 
induced by the combination of IFN and immune com-
plexes found in RA, thereby a dysregulation of IL-10 sig-
nalling by these factors contribute to pathogenesis of RA.
On the other hand, M2 macrophages, during chronic 
inflammation, produce anti-inflammatory cytokines that 
is associated with tissue remodelling and immunoregula-
tory functions, improving the pathogenesis of RA [196, 
212]. Thereby, the inhibition of macrophages should be a 
strategy of inhibiting inflammation and bone erosion in 
arthritis. Thus, the switch from a pro-inflammatory phe-
notype (M1) to an anti-inflammatory state (M2) can con-
tribute to ameliorate the disease. Their plasticity makes 
them al target for the treatment of inflammation, espe-
cially arthritis. In this regard, certain studies reported 
that M2 macrophages profile is involved in spondyloar-
thritis (SpA) pathogenesis compared to RA patients, 
while M1 mediators correlate with joint inflammation 
in RA [213]. Therefore, Ambarus et  al. [200] reported 
increased number of CD163+ macrophage (M2) phe-
notype in spondyloarthritis (SpA) synovitis, but not 
in RA, as well as these authors showed lower levels of 
M1-derived cytokines (pro-inflammatory) in SpA com-
pared with RA synovial fluid. Therefore, certain studies 
have used M2 polarizing cytokines like IL-10 as therapy 
target, showing that IL-10-treated animals exhibited sup-
pression of the development and progression of joint 
inflammation, even in established disease [214–216].
Moreover, other studies reported a possible key for 
macrophages in RA development in part by successful 
treatment of RA by anti-TNF antibodies [217–219]. The 
block TNF-α resulted in the inhibition of IL-1b, IL-6 
and IL-8 production [220–222]. Also, in RA, high levels 
of IL-17 and its receptor are found in RA synovial fluid 
and tissues [223]. In this context, researchers have sug-
gested that the IL-23/IL-17 pathway, rather than the 
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IL-12–IFN-γ axis, is essential to promoting the develop-
ment of CIA [224]. Indeed, the IL-10 inhibits IL-17 and 
RORγt expression in macrophages and suppresses mac-
rophages toward the pro-inflammatory M1 phenotype, 
which is important for the role of IL-10 in mediating the 
pathogenesis of CIA [225, 226]. In addition, M1 mac-
rophages have the ability to drive the CD4+ T helper cell 
polarization; thereby it can trigger B-cell and production 
of immunoglobulins and rheumatoid factor in synovia 
[227, 228].
These findings reveal a crosstalk between neutrophils 
and macrophages, which may result in a cascade of reac-
tions leading to the destruction of host tissues, mainly 
during inflammation chronic, associated with RA. In 
short, after the initiating event, neutrophils are one of 
the first cells attracted to the site of inflammation, which 
together with synovial macrophages or recruited release 
ROS, cytokines, chemotactic factors, and granules 
enzymes, such as collagenases, proteinases, and elastases, 
accentuating the inflammatory response that result in 
cell damage in the synovial fluid of the joints during the 
RA. Neutrophil death or degranulation or formation of 
NETs may result in the release of soluble products into 
the extracellular environment where are scavenged by 
macrophages. In addition, neutrophils and macrophages 
participate in the regulation and activation of other cell 
types such as T and B lymphocytes, dendritic cells, NK 
cells. Thus, our data suggest that mechanisms involv-
ing these cells and their mediators can be important for 
understanding both the pathology and possible therapeu-
tic interventions for RA.
Concluding remarks and future directions
As described in this review, neutrophils and macrophages 
share the same origin and also have a number of common 
functions (e.g., pathogens phagocytosis, similar kinetic 
behaviour during the process of inflammation and immu-
nomodulatory properties). Furthermore, it is well eluci-
dated that neutrophils and macrophages are important 
cells of both the innate and acquired immune response 
to fight infectious agents. However, products released 
by these cells during the inflammatory process can also 
recruit and/or activate other cell types such as epithelial 
cells, endothelial cells, platelets, T and B lymphocytes, 
NK cells, among others. Thus, these factors set contrib-
ute effectively to the development of several autoimmune 
diseases such as rheumatoid arthritis and diabetes and 
others, as well as discussed in this review.
Nonetheless, neutrophils have an important role 
recruiting and activating macrophages to the site of 
Fig. 5 A simplified schematic of the crosstalk between neutrophils/macrophages in rheumatoid arthritis
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infection or acute inflammation. Therefore, the interac-
tion of neutrophils and macrophages is a key event in 
innate immune response in the autoimmune diseases. 
In summary, during the inflammatory process, mac-
rophages migrate at the same time or after the influx of 
neutrophils into the inflamed tissue, taking a direct or 
indirect interaction between these cells. As previously 
reported, macrophages of profile M1 secrete TNF-α, 
and along with neutrophils contribute to local inflam-
mation, while M2 secrete IL-4 and IL-10 that modulate 
the inflammation, improving the tissue damage. Moreo-
ver, M1 macrophages are generated starting from cellular 
immune responses, and vital to the defence of the host. 
However, an exaggerated activation of these cells can lead 
to tissue damage as it is seen in many chronic inflamma-
tory and autoimmune diseases, including type 1 diabetes, 
rheumatoid arthritis and others. In this regards, neutro-
phils can release NETs, molecules that are associated the 
induction of several autoimmune diseases, due they acted 
as auto-antigen, as well as the excessive formation or deg-
radation failure of these NETs can lead the auto-antigens 
expression and danger-associated molecular patterns. 
Furthermore, neutrophils can migrate to lymph nodes 
and to regulate the functions of macrophages/DC, lead-
ing to cross-presentation antigens to T-cells. In addition, 
neutrophils can express MHC class II and co-stimulatory 
molecules that directly to activate superantigen-depend-
ent T-lymphocytes and help the differentiation of the 
Th1and Th17 effector T-cell subsets. Also, activated 
neutrophils may express the BLyS or BAFF that medi-
ate the T-cell–independent antibody responses of these 
cytokines, and then cooperating to activation of the 
adaptive immune responses. Thereby, many studies cor-
roborate with the knowledge that neutrophils and mac-
rophages, during infection and autoimmune diseases, 
play an important role in regulating of both T and B cells 
and activating other immune mechanisms, as shown in 
Fig. 5.
Fig. 6 A simplified schematic of the role of macrophage/neutrophil in autoimmune diseases type 1 diabetes and rheumatoid arthritis
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However, the major limitation currently facing these 
studies is the lack of studies that relate the functions in 
sets of cells involved in the pathogenesis of autoimmune 
diseases. This is likely due to the complexity of measur-
ing the interactions among neutrophils and macrophages 
and their mediators that are involved in these disorders. 
Most studies focus on these characteristics of a tar-
geted cell or molecule under in  situ conditions. Impor-
tant questions thus persist regarding, for instance, how 
to relate the plasticity and diversity of macrophages and 
neutrophils, which are quite important in mediating the 
innate and adaptive immune responses leading to tissue 
damage in type 1 diabetes and rheumatoid arthritis, as 
well as how these factors may help to develop multiple 
interventions that address the inflammatory responses 
and tolerogenic roles of these cells in these diseases, as 
shown in Fig. 6. However, future studies might examine 
whether therapeutic interventions that simultaneously 
modulate certain roles of macrophages and neutrophils 
can also improve of symptoms and prevent organ dam-
age in autoimmune diseases. These findings remain to be 
clarified in order to elucidate the immune mechanisms 
involving several cell types and soluble factors released to 
injured tissue.
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